Companies with Curative Ambition

Aevum is pioneering the discovery and development of therapeutic molecules derived from exercised muscle to treat diseases that are known to benefit from exercise. Our lead program is being developed for the treatment of Parkinson’s disease and other related neurodegenerative disorders.

Cenos is developing a blood-brain barrier shuttle platform for the treatment of neurological diseases of high unmet need. We combine innovative delivery technologies with comprehensive therapeutic development expertise to drive meaningful impact for patients.

Clasp is pioneering precision in immuno-oncology through next-generation T cell engagers (TCEs) that target tumor-specific oncogenic driver mutations common across hard-to-treat cancers. With their unique properties, our TCEs are adaptable for application across a variety of cancers with high unmet need.

Crosslink is engineering cancer medicines that conditionally assemble in the tumor microenvironment. Our technology can be adapted to multiple therapeutic modalities, improving safety and efficacy.

Advancing off-the-shelf dopamine neuron replacement therapies as a disease-modifying and potentially curative treatment for neurological disorders. Our proprietary platform leverages a novel approach to treating central nervous system disorders, such as Parkinson’s disease, by replacing neurons lost due to neurodegeneration.

Kobuk is developing precision biologics to treat autoimmune and inflammatory diseases, focusing on achieving exceptional safety and broad therapeutic reach.

Permeasis utilizes its proprietary delivery technology to promote the intracellular delivery of a broad range of membrane impermeable cargo proteins. The technology allows the creation of a novel class of therapeutics (“intracellular biologics”) designed to address unmet medical needs outside the reach of traditional small molecules or biologics.

Recuro is an integrated digital health solutions company that takes a uniquely personalized and proactive approach to virtual care. Unlike other traditional virtual care solutions today, Recuro has created a virtual-first care delivery platform that provides a holistic suite of virtual care services, integrated labs and supplemental benefits that consumers can choose from to design a digital health solution. Recuro’s core virtual care offerings include primary care, behavioral health, and urgent care, with supplemental benefits spanning pharmacy, care management, advocacy, and physician locator.

With a novel approach to precision oncology, Tasca Therapeutics is unlocking post-translational modification of proteins by utilizing our state-of-the-art chemical biology and computational approaches, and combining with inhibition at key metabolic nodes to generate drugs for previously considered undruggable targets. Tasca is focused on using its proprietary platform to develop small molecule drugs for hard-to-treat oncology indications.

Tortugas is developing therapeutics for neurological diseases of high unmet need. We focus on translational approaches to allow for rapid identification of efficacy and impact.

Developing a novel antibody-enzyme fusion to target tumors and trigger the robust immune response known as hyper-acute rejection. By leveraging the natural power of the immune response system, we are able to utilize fusion protein technology to attack difficult tumor targets throughout the body.